AstraZeneca's
stock has witnessed steady gains recently, owing to its strong performance across growth franchises.
Goldman Sachs has recommended a
buy for AstraZeneca, suggesting that the healthcare giant's stocks are undervalued. The company's stocks rose following solid third-quarter results and confirmed outlook. Highlights from AstraZeneca's earnings call indicate a strong growth trajectory and future ambitions. Furthermore, AstraZeneca's profitability surged 77% to $2.53 billion during Q3, with expansion in the U.S market and strong performance in cancer drug sales. Thid backs the FY25 outlook, also leads to a jump in share prices. Meanwhile, great expectations are set for AstraZeneca's performance in the long-term being listed directly on the
New York Stock Exchange. Positively received by investors, the pharmaceutical mammoth's stock has experienced a 15% increase YTD. However, AstraZeneca's future is not devoid of challenges, as Deutsche bank downgraded its stock to sell due to concerns over the pipeline. Yet, the company's US drug pricing deal mitigates threats of tariffs and price controls, promising manageable impact in 2026. With robust growth plans and strategic US expansion, AstraZeneca's future remains promising.
AstraZeneca Stocks News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sun, 09 Nov 2025 00:34:54 GMT -
